1187449-01-9

Basic information

• Product Name: 2-Amino-4-bromo-5-chloropyridine
• Synonyms: 2-Amino-4-bromo-5-chloropyridine;4-BroMo-5-chloro-pyridin-2-ylaMine;4-BroMo-5-chloropyridin-2-aMine
• CAS NO: 1187449-01-9
• Molecular Formula: C₅H₄BrClN₂
• Molecular Weight: 207.45566
• Mol File: 1187449-01-9.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 299.8±35.0 °C(Predicted)
• Appearance: /
• Density: 1.834±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 3.63±0.24(Predicted)
• CAS DataBase Reference: 2-Amino-4-bromo-5-chloropyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Amino-4-bromo-5-chloropyridine(1187449-01-9)
• EPA Substance Registry System: 2-Amino-4-bromo-5-chloropyridine(1187449-01-9)

Safety Data

• Hazardous Substances Data: 1187449-01-9(Hazardous Substances Data)

Usage

General Description

2-amino-4-bromo-5-chloropyridine is a chemical compound with the molecular formula C5H3BrClN2. Its systematic name is 2-amino-4-bromochloropyridine, and it is commonly used in the field of organic synthesis. 2-amino-4-bromo-5-chloropyridine, which appears as beige-brown crystals, features both bromine and chlorine substitutions on a pyridine ring, making it useful in various chemical reactions. It has a molar mass of 225.95 g/mol. While there are no specific safety or hazard ratings for this compound, general lab safety and chemical handling procedures should be followed while handling it. It should be noted that direct contact with the eyes or skin can cause irritation.

Upstream product

• 84249-14-9 2-amino-4-bromopyridine 

Relevant articles and documents

Discovery of AZD4573, a Potent and Selective Inhibitor of CDK9 That Enables Short Duration of Target Engagement for the Treatment of Hematological Malignancies

A CDK9 inhibitor having short target engagement would enable a reduction of Mcl-1 activity, resulting in apoptosis in cancer cells dependent on Mcl-1 for survival. We report the optimization of a series of amidopyridines (from compound 2), focusing on properties suitable for achieving short target engagement after intravenous administration. By increasing potency and human metabolic clearance, we identified compound 24, a potent and selective CDK9 inhibitor with suitable predicted human pharmacokinetic properties to deliver transient inhibition of CDK9. Furthermore, the solubility of 24 was considered adequate to allow i.v. formulation at the anticipated effective dose. Short-term treatment with compound 24 led to a rapid dose- and time-dependent decrease of pSer2-RNAP2 and Mcl-1, resulting in cell apoptosis in multiple hematological cancer cell lines. Intermittent dosing of compound 24 demonstrated efficacy in xenograft models derived from multiple hematological tumors. Compound 24 is currently in clinical trials for the treatment of hematological malignancies.

Chemical Compounds

Provided are a series of novel pyridine or pyrimidine derivatives which inhibit CDK9 and may be useful for the treatment of hyperproliferative diseases. In particular the compounds are of use in the treatment of proliferative disease such as cancer including hematological malignancies such as acute myeloid leukemia, multiple myeloma, chronic lymphocytic leukemia, diffuse large B cell lymphoma, Burkitt's lymphoma, follicular lymphoma and solid tumors such as breast cancer, lung cancer, neuroblastoma and colon cancer.

Dihydropyrazole GPR40 modulators

The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are GPR40 G protein-coupled receptor modulators which may be used as medicaments.